

<p>1.</p>	<p>Treatment & Condition</p> <p>Bimekizumab for treating moderate to severe plaque psoriasis</p>
<p>2.</p>	<p>Associated appraisal body & Summary of ruling</p> <p>NICE Technology Appraisal guidance TA723 (September 2021)</p> <p>2.1 Bimekizumab is recommended as an option for treating plaque psoriasis in adults, only if:</p> <ul style="list-style-type: none"> • the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and • the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and • the company provides the drug according to the commercial arrangement. <p>2.2 Stop bimekizumab treatment at 16 weeks if the psoriasis has not responded adequately. An adequate response is defined as:</p> <ul style="list-style-type: none"> • a 75% reduction in the PASI score (PASI 75) from when treatment started or • a 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from when treatment started. <p>2.3 Choose the least expensive treatment if patients and their clinicians consider bimekizumab to be one of a range of suitable treatments (taking into account availability of biosimilar products, administration costs, dosage, price per dose and commercial arrangements).</p> <p>2.4 Take into account how skin colour could affect the PASI score and make any appropriate clinical adjustments.</p> <p>2.5 Take into account any physical, psychological, sensory or learning disabilities, or communication difficulties that could affect the responses to the DLQI and make any appropriate adjustments.</p> <p>2.6 These recommendations are not intended to affect treatment with bimekizumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.</p>
<p>3.</p>	<p>Number of people in Northern Ireland expected to take up service/therapy</p> <p>Implementation of this guidance offers an additional treatment option for treating</p>

	<p>moderate to severe plaque psoriasis.</p> <p>The NICE resource impact statement indicates that the guidance is not expected to have an impact on resources. This is because the technology is a further treatment option and is available at a similar price to the current treatment options.</p>
4.	<p>Patient Access Scheme Availability</p> <p>(<u>Yes</u>/No)</p> <p>The company (UCB Pharma) has a commercial arrangement. This makes bimekizumab available to the NHS with a discount. The size of the discount is commercial in confidence.</p>
5.	<p>Infrastructure Requirements</p> <p>It is anticipated that infrastructure requirements will be minimal.</p> <p>Infrastructure requirements for the delivery of all biologics are reviewed annually as part of the routine commissioning arrangements for supporting growth in the provision of these therapies.</p>
6.	<p>Expected implementation period</p> <p>There is no impediment to immediate implementation for new patients.</p>
7.	<p>Commissioning arrangements</p> <p>This drug will be formally commissioned by HSCB/PHA via the Specialist Services Commissioning Team.</p>
8.	<p>Monitoring arrangements</p> <p>The HSC Board has robust arrangements in place for the quarterly monitoring of all biologic therapies (activity/cost and waiting times) and this regime will be included within the routinely provided return.</p> <p>All monitoring returns for biologics are reviewed by the specialist services commissioning team quarterly.</p>
9.	<p>DoH (NI) Legislative/Policy Caveats</p> <p>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.</p> <p>The Rural Needs Act NI 2016 has been considered and this guidance, which is purely of a technical nature, is not regarded as falling within the scope of the act.</p>